New hope for IgG4 patients: which drug combo works best?
NCT ID NCT05789030
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests two treatment plans for people with IgG4-related disease affecting superficial organs like glands or skin. One group gets prednisone plus iguratimod, the other gets prednisone plus leflunomide. Over 12 months, researchers will track how many patients have a relapse and how long it takes for symptoms to return. The goal is to find a safer, more effective way to keep the disease under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
prednisone plus iguratimod or prednisone plus leflunomide
What this could lead to
If successful, this could identify a more effective and safer drug combination to control IgG4-related disease and reduce relapses.
What could go wrong
This is a small, early-stage trial with only 60 participants, so results may not apply to all patients. Both treatments involve steroids and immune-suppressing drugs, which can have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGG4-RELATED DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking Union Medical College Hospital
RECRUITINGBeijing, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••